AU
UK
CA
NZ
IND
US
Shares of HCW Biologics Inc. (NASDAQ:HCWB) closed at USD 0.60 on February 18, down USD 0.049 or 7.54% for the session. The decline followed the company’s announcement of a USD 1.5 million follow-on offering priced at-the-market under Nasdaq rules. The pricing of the new …
Genmab A/S – ADR (NASDAQ:GMAB)closed at $30.03 on February 13, 2026, gaining $0.44 in the session, as Morgan Stanley maintained its Equal Weight rating and set a $34.00 price target. The brokerage view reflects a more neutral stance compared with several firms that continue …
Eli Lilly and Company (NYSE:LLY) has announced plans to investmore than US$3.5 billionin a new manufacturing facility inPennsylvania’s Lehigh Valley, reinforcing its aggressive capacity expansion strategy. Construction is expected to begin in 2026, with the site becoming operational in2031.
Tenet Healthcare (NYSE:THC) has become a focal point for market watchers after a flurry of research updates in early 2026. The company reported quarterlyearningsof $4.70 per share, surpassing analyst forecasts of $4.08, while revenue climbed to $5.53 billion, up 8.9% from the prior year. …
McKesson Corp (NYSE:MCK), a major U.S.-based healthcare distribution company, continues to receive a positive reception from market analysts. According to EODHD/Others data as of 11Feb 2026, Current consensus data reflects a Buy rating, with a target price of USD 957.17, implying an estimated upside …
Adaptive Biotechnologies (NASDAQ:ADPT) has experienced notable fluctuations in recent trading sessions, with the stock declining 14.76% over the past five days compared with a 13.16% drop in theNasdaq Compositeindex and a 10.92% decline in the biotechnology sector. Over a one-month period, shares fell 2.11%, …
Natural Health Trends Corp. (NASDAQ:NHTC), a direct-selling and e-commerce company operating under the NHT Global brand, reported fourth-quarter revenue of $9.7 million. This represented a 3% increase from the third quarter of 2025 but a 10% decline compared with the fourth quarter of 2024.
Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on therapies addressing central nervous system disorders, announced operational and financial results for the second quarter of fiscal 2026. The update included financial performance details alongside progress on the United States commercialization of EXXUA, an FDA-approved …
Protagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing orally administered peptide-based therapies for immune-mediated and other serious diseases. The company applies its proprietary Peptide 2.0 platform to design molecules targeting G protein–coupled receptors and cytokine receptors, aiming to provide oral alternatives …
Please wait processing your request...